Boston Dynamics unveils first commercial Atlas humanoid robot
Boston Dynamics has launched its first commercially deployable Atlas humanoid robot at CES 2026.

Finance journalist at Grafa. Covers tech, crypto, and markets, making complex finance clear for all. Passionate about innovation and trends.
Boston Dynamics has launched its first commercially deployable Atlas humanoid robot at CES 2026.
Polymarket is expanding its prediction markets to cover possible future US geopolitical actions after heavy trading linked to Venezuela.
Eastern Metals (ASX:EMS) has recommenced trading on the Australian Securities Exchange following its acquisition of Raptor Resources.
5E Advanced Materials (ASX:5EA), a developer of refined borates and advanced boron derivative materials, announced that its boric acid has successfully passed all qualification parameters in a 20-ton commercial tank trial conducted by a major US-based LCD glass manufacturer.
Aristocrat Leisure (ASX:ALL) has announced an expansion of its on-market share buyback program, increasing the total value to $1.5 billion as part of its ongoing capital management strategy.
Rio Tinto (ASX:RIO) has confirmed talks on a potential combination with Glencore involving some or all of their businesses.
The Buckle (NYSE:BKE) reported robust sales performance for the five-week fiscal month ended January 3, 2026, a period encompassing the critical holiday shopping season.
Net sales increased 6.5% to $215.3 million from $202.1 million in the prior-year five-week period ended January 4, 2025.
RPM International (NYSE:RPM), a world leader in specialty coatings, sealants and building materials, reported record fiscal second-quarter sales of $1.91 billion for the period ended November 30, 2025, representing a 3.5% increase over the prior-year record.
Helen of Troy Limited (NASDAQ:HELE) reported third-quarter fiscal 2026 results that reflected ongoing headwinds in the consumer discretionary sector.
NervGen Pharma Corp. (NASDAQ:NGEN) officially began trading on the Nasdaq Stock Market on January 8, marking a transition into a late-stage biopharmaceutical player.